Premium
Prophylaxis and treatment of thromboembolic diseases during pregnancy with dalteparin
Author(s) -
Rey E.,
Rivard G.E.
Publication year - 2000
Publication title -
international journal of gynecology and obstetrics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.895
H-Index - 97
eISSN - 1879-3479
pISSN - 0020-7292
DOI - 10.1016/s0020-7292(00)00290-3
Subject(s) - medicine , pregnancy , therapeutic index , low molecular weight heparin , heparin , obstetrics , anesthesia , therapeutic effect , prophylactic treatment , dosing , drug , pharmacology , genetics , biology
Objectives : To determine if a prophylactic dose of dalteparin, 5000 IU daily, and if the adjusted‐weight dalteparin therapeutic dose of 100 IU/kg twice daily are appropriate in pregnancy. Method : Anti‐Xa activity levels were used to assess prophylactic (33 women) and therapeutic (15 women) dalteparin dosage throughout pregnancy. Analysis of variance was used and P ‐values less than 0.05 were considered statistically significant. Results : In the prophylactic group, anti‐Xa activity levels did not vary significantly throughout pregnancy ( P =0.15). The initial dalteparin dose was modified on the first anti‐Xa activity measurement in eight women, whose weight was statistically different from those remaining on the initial dose ( P <0.001). The adjusted‐weight therapeutic dalteparin dose induced adequate anti‐Xa activity levels. Conclusions : Dalteparin, 5000 IU daily, is suitable for most pregnant women and does not need to be modified in the third trimester. A therapeutic dalteparin dose adjusted according to pregnancy weight is appropriate.